Anti-GD2 CAR T Cells
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Anti-GD2 CAR T Cells, covering 2024-05-16 to 2025-02-05. Get the full timeline:
Most recent: Clinical Trial Update: Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors [Phase 1, Phase 2]